// App-Quantinova.ai

5013 : Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).

Researchers

Presenter

  • Praful Kumar Ravi

Principal Investigators

  • Joaquin Mateo

  • Zafeiris Zafeiriou

  • Gerhardt Attard

  • Spyridon Sideris

  • Emily Grist

  • Alan D. Smith

  • Sophia Wong

  • David Lorente

  • Diletta Bianchini

Medical Centers

  • Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer ResearchThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved